Performance analysis of Outlook Therapeutics (OTLK)
Annual Return
Over the past 3 years, OTLK has had an average annual return of -66.04%, underperforming the benchmark SPY, which returned +19.31% annual.
Over the past 5 years, OTLK has had an average annual return of -51.28%, underperforming the benchmark SPY, which returned +12.55% annual.
Over the past 10 years, OTLK has had an average annual return of -44.84%, underperforming the benchmark SPY, which returned +14.95% annual.
Since Jun 14, 2016, OTLK has had an average annual return of -45.94%, underperforming the benchmark SPY, which returned +15.29% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -13.04% | -17.86% | -75.65% | -63.61% | -20.60% | +4.46% | +120.23% | -85.23% | -61.53% | -56.82% | -29.51% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -73.91% | +0% | -50.00% | +33.33% | +175% | +109.09% | -13.04% | -13.04% | |||||
| 2025 | +7.14% | -26.67% | -18.18% | +27.78% | +17.39% | -14.81% | +26.09% | -58.62% | +33.33% | +12.50% | +44.44% | -11.54% | -17.86% |
| 2024 | -1.74% | +13.27% | +36.72% | -25.14% | -21.37% | +4.85% | +4.63% | -4.42% | -27.78% | +7.69% | -64.29% | -6.67% | -75.65% |
| 2023 | +6.65% | -5.34% | +0% | -3.76% | +43% | +15.95% | -0.59% | -86.76% | -2.99% | +170.77% | -19.89% | -18.44% | -63.61% |
| 2022 | +4.52% | +14.66% | +9.22% | -12.86% | -25.77% | -11.28% | +10.70% | -0.91% | +8.84% | -4.76% | -10.59% | +3.95% | -20.60% |
| 2021 | -28.08% | +131.75% | +3.78% | +5.77% | +12.63% | -7.13% | -9.19% | +22.05% | -21.41% | -4.57% | -27.06% | -9.95% | +4.46% |
| 2020 | +56.07% | -17.78% | -20.72% | +12.50% | +51.01% | +26.42% | +5.29% | -51.51% | +9.33% | +8.06% | +53.95% | +8.55% | +120.23% |
| 2019 | +53.03% | +45.09% | -16.69% | -82.96% | +90.51% | -13.37% | +11.99% | -34.31% | -2.68% | -12.16% | -20.63% | -43.09% | -85.23% |
| 2018 | -12.29% | -0% | -21.95% | +2.35% | +3.19% | -10.09% | +0.61% | +1.86% | +13.17% | +1.05% | -35.14% | -22.14% | -61.53% |
| 2017 | +18.27% | -10.39% | -16.00% | -16.41% | -32.14% | -34.21% | -0% | -13.19% | +57.80% | -8.01% | -2.37% | +5.66% | -56.82% |
Drawdown analysis of Outlook Therapeutics (OTLK)
The maximum drawdown for the OTLK was -99.98%, occurring on Mar 24, 2026. This drawdown has not yet recovered.
The current OTLK drawdown is -99.84%.
Since Jun 14, 2016 OTLK has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 2 times
- 10% or more: 2 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.98% | Sep 6, 2016 | 2399 | Mar 24, 2026 | Ongoing | Ongoing | Ongoing |
| -29.29% | Jun 16, 2016 | 33 | Aug 3, 2016 | 20 | Aug 31, 2016 | 53 |
| -3.06% | Sep 1, 2016 | 1 | Sep 2, 2016 | 1 | Sep 6, 2016 | 2 |
| -1.71% | Jun 14, 2016 | 1 | Jun 15, 2016 | 1 | Jun 16, 2016 | 2 |